切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2023, Vol. 17 ›› Issue (10) : 1027 -1032. doi: 10.3877/cma.j.issn.1674-0785.2023.10.001

所属专题: 乳腺疾病

临床研究

初始腋窝淋巴结转移乳腺癌新辅助治疗后腋窝病理完全缓解的预测因素分析
牟鳄贤, 李卓璇, 董浩, 于淼, 纪娟, 徐佳, 王浩, 刘世伟()   
  1. 610041 成都,四川省肿瘤临床医学研究中心 四川省肿瘤医院研究所 四川省癌症防治中心 电子科技大学附属肿瘤医院乳腺科
    610041 成都,四川省肿瘤临床医学研究中心 四川省肿瘤医院研究所 四川省癌症防治中心 电子科技大学附属肿瘤医院病理科
    610041 成都,四川省肿瘤临床医学研究中心 四川省肿瘤医院研究所 四川省癌症防治中心 电子科技大学附属肿瘤医院整形外科
  • 收稿日期:2023-09-13 出版日期:2023-10-15
  • 通信作者: 刘世伟
  • 基金资助:
    四川省科技计划资助(2023YFS0103); 四川省自然科学基金资助(2022NSFSC0707); 四川省抗癌协会2022年(齐鲁)科研专项资金资助(XH2022515); 四川省干部保健科研课题(川干研2021-802)

Predictive factors for axillary pathological complete response in initially node-positive breast cancer patients treated with neoadjuvant therapy

Exian Mou, Zhuoxuan Li, Hao Dong, Miao Yu, Juan Ji, Jia Xu, Hao Wang, Shiwei Liu()   

  1. Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China
    Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China
    Department of Plastic and Reconstructive Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China
  • Received:2023-09-13 Published:2023-10-15
  • Corresponding author: Shiwei Liu
引用本文:

牟鳄贤, 李卓璇, 董浩, 于淼, 纪娟, 徐佳, 王浩, 刘世伟. 初始腋窝淋巴结转移乳腺癌新辅助治疗后腋窝病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2023, 17(10): 1027-1032.

Exian Mou, Zhuoxuan Li, Hao Dong, Miao Yu, Juan Ji, Jia Xu, Hao Wang, Shiwei Liu. Predictive factors for axillary pathological complete response in initially node-positive breast cancer patients treated with neoadjuvant therapy[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(10): 1027-1032.

目的

探索初始腋窝淋巴结转移(cN+)乳腺癌新辅助治疗(NAT)后腋窝病理完全缓解(apCR)的临床病理预测因素。

方法

回顾性分析四川省肿瘤医院乳腺科2016年6月至2023年4月经治的cN+且接受NAT的乳腺癌病例。根据术后病理结果,分为apCR组及非apCR组,比较两组临床病理特点的差异,探索apCR的预测因素。

结果

共计486例患者纳入本研究,总体apCR率为50.4%(245/486)。单因素分析显示,组织学分级、雌激素受体状态、孕激素受体状态、人类表皮生长因子受体2(HER2)状态、Ki67、临床疗效评价及是否达到乳房病理完全缓解(bpCR)与apCR具有相关性(P均<0.05)。多因素分析表明,HER2阳性(P<0.001)、临床疗效评价较佳(P=0.047)及bpCR(P<0.001)是apCR的独立预测因素。建立的apCR预测模型受试者工作特征(ROC)曲线下面积(AUC)为0.793(95%CI:0.753~0.833),敏感度为68.0%,特异度为81.1%。HER2阳性、临床疗效评价为完全缓解或部分缓解且达到bpCR者72例,其apCR率达93.1%(67/72)。HER2阳性、临床疗效评价为完全缓解且达到bpCR者6例,其apCR率为100%(6/6)。

结论

初始cN+接受NAT的HER2阳性、临床疗效评价较佳或病理疗效达到bpCR的乳腺癌,腋窝残留肿瘤负荷的风险较低,可作为豁免腋窝淋巴结清扫研究的目标人群。

Objective

To identify the predictive factors for axillary pathological complete response (apCR) in initially node-positive (cN+) breast cancer patients treated with neoadjuvant treatment (NAT).

Methods

Data of cN+ breast cancer patients treated with NAT at the Breast Department of Sichuan Cancer Hospital from June 2016 to April 2023 were retrospectively reviewed. Clinicopathological characteristics were compared between patients with and without apCR. Univariate and multivariate analyses were conducted for identifying the predictive factors for apCR.

Results

A total of 486 patients were included and the overall apCR rate was 50.4% (245/486). In the univariate analysis, histological grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, Ki-67 index, clinical response, and breast pathological complete response (bpCR) were associated with apCR (P<0.05). Multivariate analysis demonstrated that HER2 positivity (P<0.001), better clinical response, (P=0.047), and bpCR (P<0.001) were independent predictors of apCR. The area under the receiver operating characteristic curve of the prediction model of apCR in cN+ breast cancer patients treated with NAT was 0.793 (95% confidence interval: 0.753-0.833), with a sensitivity of 68.0% and specificity of 81.1%.

Conclusion

In cN+ breast cancer patients treated with NAT, those with HER2 positive disease, better clinical response, or bpCR have a lower risk of axillary residual disease, and can be candidates for de-escalating surgical research.

图1 研究病例纳入流程图
表1 临床病理因素与apCR相关性的单因素分析
临床病理特点 例数(n=486) apCR(n=245) 非apCR(n=241) 统计值 P
年龄(岁, 50.13±9.91 49.38±9.06 50.83±10.65 t=1.381 0.191
BMI( 24.23±3.20 24.18±10.04 24.28±3.24 t=0.368 0.717
cT[例(%)] χ2=4.802 0.308
0 2 1(50.0) 1(50.0)
1 37 17(45.9) 20(54.1)
2 358 190(53.1) 168(46.9)
3 63 28(44.4) 35(55.6)
4 26 9(34.6) 17(65.4)
cN[例(%)] χ2=1.208 0.547
1 333 172(51.7) 161(48.3)
2 79 40(50.6) 39(49.4)
3 74 33(44.6) 41(55.4)
组织学类型[例(%)] χ2=0.853 0.653
浸润性导管癌 475 240(51.7) 235(48.3)
浸润性小叶癌 8 3(37.5) 5(62.5)
其它类型 3 2(66.7) 1(33.3)
组织学分级[例(%)] χ2=15.994 <0.001
I~II 238 101(42.4) 137(57.6)
III 124 80(64.5) 44(35.5)
NA 124 64(51.6) 60(48.4)
ER[例(%)] χ2=17.718 <0.001
阴性 161 103(64.0) 58(36.0)
阳性 325 142(43.7) 183(56.3)
PgR[例(%)] χ2=17.511 <0.001
阴性 199 123(61.8) 76(38.2)
阳性 287 122(42.5) 165(57.5)
HER2[例(%)] χ2=85.460 <0.001
阴性 313 109(34.8) 204(65.2)
阳性 173 136(78.6) 37(21.4)
Ki67[例(%)] χ2=7.148 0.008
<14% 61 22(36.1) 39(63.9)
≥14% 425 223(52.5) 202(47.5)
乳房手术方式[例(%)] χ2=0.051 0.821
乳房全切 451 228(50.6) 223(49.4)
保留乳房 35 17(48.6) 18(51.4)
临床疗效评价[例(%)] χ2=21.729 <0.001
CR 15 12(80.0) 3(20.0)
PR 344 189(54.9) 155(45.1)
SD 117 39(33.3) 78(66.7)
PD 10 5(50.0) 5(50.0)
bpCR[例(%)] χ2=71.526 <0.001
340 129(37.9) 211(62.1)
146 116(79.5) 30(20.5)
表2 临床病理因素与apCR相关性的多因素分析[例(%)]
图2 初始腋窝淋巴结转移乳腺癌新辅助治疗后腋窝病理完全缓解的预测模型 注:ROC为受试者工作特征曲线;AUC为曲线下面积
1
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes [J]. J Clin Oncol, 2012, 30(15): 1796-1804.
2
Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer[J]. Ann Surg, 2019, 269(3): 432-442.
3
Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010, 28(16): 2784-2795.
4
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in beast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update [J]. J Clin Oncol, 2018, 36(20): 2105-2122.
5
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up [J]. Histopathology, 2002, 41(3a): 151-152.
6
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
7
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: A review [J]. JAMA Oncol, 2016, 3(4): 549-555.
8
牟鳄贤, 王浩, 夏莉, 等. 超声造影联合单染料法前哨淋巴结活检术在初始腋窝淋巴结转移HER2阳性及三阴型乳腺癌中的应用研究 [J/OL]. 中华临床医师杂志(电子版), 2022, 16(11): 1068-1074.

URL    
9
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial [J]. JAMA, 2013, 310(14): 1455-1461.
10
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
11
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study [J]. J Clin Oncol, 2014, 33(3): 258-264.
12
Hasegawa S, Asahi S. The efficacy of combined use of pertuzumab and trastuzumab-based neoadjuvant chemotherapy for HER2 positive breast cancer [J]. Gan To Kagaku Ryoho, 2021, 48(13): 1822-1824.
13
Pathak N, Sharma A, Elavarasi A, et al. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level meta-analysis [J]. Breast, 2022, 64: 7-18.
14
刘世伟, 张蒲蓉, 曾石岩, 等. HER-2阳性乳腺癌新辅助治疗腋窝病理完全缓解的预测因素分析 [J]. 现代肿瘤医学, 2021, 29(3): 410-413.
15
甘良雨, 辛灵, 程元甲, 等. 乳腺癌腋窝淋巴结转移患者新辅助化疗后腋窝病理完全缓解的相关因素分析 [J/OL]. 中华临床医师杂志(电子版), 2021, 15(10): 768-773.

URL    
16
Cha C, Ahn SG, Kim D, et al. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer [J]. Int J Cancer, 2021, 149(8): 1585-1592.
17
Ryu JM, Choi HJ, Park EH, et al. Relationship between breast and axillary pathologic complete response according to clinical nodal stage: A nationwide study from Korean breast cancer society [J]. J Breast Cancer, 2022, 25(2): 94-105.
18
Heil J, Sinn P, Richter H, et al. RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial [J]. BMC Cancer, 2018, 18(1): 851.
19
Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy [J]. Ann Surg, 2018, 267(5): 946-951.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[4] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[5] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[6] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[7] 高建新, 王啸飞, 于淼, 路夷平. 局部进展期直肠癌新辅助治疗后行ISR术远切缘距离的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 539-543.
[8] 李阳, 董峰, 曾立鹏. 局部进展期直肠癌新辅助治疗后腹腔镜TaTME与TME中的对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 547-550.
[9] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[10] 中国抗癌协会结直肠肿瘤整合康复专业委员会, 北京癌症防治学会直肠癌新辅助治疗专业委员会. 直肠癌新辅助治疗相关恶心、呕吐副反应的预防、诊断及治疗指南[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 353-361.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要